Duration & Timing: which factors matter when evaluating exposure duration?

• A. Single use vs continuous use; latency
• B. Only the length of exposure
• C. Randomization approach
• D. Drug class specificity

Answer: (A)

When evaluating exposure duration, the crucial elements are how the exposure occurs over time and the delay between exposure and the outcome. The pattern of exposure—whether it happens as a one-time event or as ongoing/continuous use—can change the biological impact, because dose rate and periods of susceptibility influence risk. Latency—the time from exposure to the development or detection of the outcome—also matters, especially for diseases with long incubation periods, where effects may only appear years later. Together, these aspects capture the real-world complexity of exposure duration beyond simply measuring how long exposure lasts.

This is why the best choice includes both single use versus continuous use and latency. Focusing only on the length of exposure ignores how the exposure was delivered and when the effect is expected to emerge. Randomization approach pertains to study design rather than duration of exposure, and drug class specificity relates to what is being exposed rather than how the exposure unfolds over time.